Joel Greenblatt Nektar Therapeutics Transaction History

Gotham Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $5.72 Million - $8.39 Million	-181,095 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $4.07 Million - $7.58 Million	-133,892 Reduced 42.51%	181,095 $5.95 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $14.4 Million - $21.3 Million	310,878 Added 7565.78%	314,987 $19.2 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $15,678 - $35,408	-339 Reduced 7.62%	4,109 $201,000
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $11,480 - $21,688	-200 Reduced 4.3%	4,448 $473,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $106,996 - $281,204	4,648	4,648 $278,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $212M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.